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ABSTRACT
Aim. This study analyzed the incidence, time course, and risk factors associated with
dyslipidemia during the first year after kidney transplantation among patients receiving
various immunosuppressive regimens.
Methods. The analysis included 474 kidney transplant recipients receiving cyclosporine
(CSA) combined with sirolimus (SRL; n  137) or mycophenolate (MMF, n  58) or
everolimus (EVR, n  47); or SRL combined with MMF (n  32); or tacrolimus (TAC)
combined with SRL (n  86) or MMF (n  114). All patients received prednisone. We
evaluated the influence of demographic features, clinical outcomes, and statin use on lipid
profiles during the first year after transplantation. total cholesterol (TC), triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), non-HDL-C, TC:HDL-C, LDL-C:HDL-C, TG:HDL-C.
Results. Lipid profiles were within the recommended ranges in 28% of patients
pretransplantation and in 10% at 1 year; 27% of them received statins. At 1 year, LDL-C
100 mg/dL was observed in 31.8% of patients but more than 35% of these patients still
showed other lipid fractions or ratios outside recommended target concentrations. Among
all patients with LDL-C  100 mg/dL, almost 70% to 80% had other lipid fractions or
ratios within target ranges. A logistic regression analysis showed age, gender, time on
dialysis, diabetes, type of calcineurin inhibitor (CSA vs TAC), adjunctive therapy
(SRL/EVR vs MMF) and prednisone dose to be associated with dyslipidemia.
Conclusion. Dyslipidemia is frequent at 1 year after transplantation. The lack of
agreement among changes observed in lipid fractions and ratios suggests that more studies
are necessary to guide therapy besides targeting LDL-C concentrations as recommended
by current guidelines.
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cDYSLIPIDEMIA, which shows a high prevalence in allstages of renal disease, has been associated with
increased cardiovascular morbidity and mortality1 as well as
ossibly late graft failure.2 In addition to all of the risk
factors of the general population, the presence of impaired
allograft function, proteinuria, an acute rejection episode
and its treatment with corticosteroids, new-onset diabetes
mellitus after transplantation and various types and doses
of immunosuppressive agents also contribute as risk factors
among the kidney transplant population.3,4
Several guidelines defining the type, severity, and targets
for therapeutic interventions of dyslipidemia have been
implemented. They focus on total cholesterol (TC) and/or
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3730ow-density lipoprotein cholesterol (LDL-C) concentra-
ions. Evidence supporting the importance of lowering
DL-C concentrations to decrease the risk of cardiovascu-
ar events. Nevertheless, a significant number of cardiovas-
ular events occured5 even in trials that achieved substantial
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LIPID PROFILE AFTER KIDNEY TRANSPLANTATION 3731reductions in LDL-C. Targeting LDL-C concentrations may
miss other lipid abnormalities, underestimate cardiovascu-
lar risk, and hamper adequate treatment. Current preven-
tion guidelines also support optimal high-density lipopro-
tein cholesterol (HDL-C) and triglyceride (TG)
concentrations to further reduce the incidence of cardio-
vascular events.6 Furthermore, reduction in the atherogenic
non- non-HDL-C lipid fraction7 may be superior to LDL-C
o predict cardiovascular events.8
There is no consensus regarding the utility of TC:
HDL-C, LDL:HDL-C, or TG:HDL-C ratios to predict
coronary heart disease risk. TC:HDL-C ratio is a useful
summary of the joint contribution of TC and HDL-C to
coronary heart disease risk.9 An high LDL-C:HDL-C ratio
ombined with hypertriglyceridemia (lipid triad) has been
escribed as atherogenic dyslipidemia, which was associ-
ted with highest coronary heart disease risk.8,10 Finally,
TG:HDL-C ratios, a marker for the presence of highly
atherogenic small-dense LDL, are also an important lipid
ratio to assess atherogenic potential mainly with the pres-
ence of insulin resistant metabolic syndrome.11 Our study
nalyzed the effect of demographic characteristics, clinical
utcomes, and maintenance immunosuppressive regimens
n temporal changes in lipid profiles during the first year
fter kidney transplantation.
METHODS
This retrospective single-center study compared the incidence,
time course, and severity of dyslipidemia among renal transplant
patients treated with six different immunosuppressive regimens for
up to 12 months. Data were captured from individual files of
patients who had previously participated in prospective random-
ized clinical trials conducted in accordance with the International
Conference of Harmonization and good clinical practice. All study
protocols had been approved by an independent local Ethics
Committee.
Population
For this analysis, we selected first living related or deceased kidney
transplant recipients performed between March 6, 1999, and
December 5, 2006, who were older than 13 years with pretransplant
total white blood cell count4.0 103/mm3, platelet count100.0
103/mm3, fasting cholesterol 300 mg/dL, and fasting TG 400
g/dL.
Immunosuppressive Regimens
We evaluated six immunosuppressive regimens: cyclosporine
(CsA) with sirolimus (SRL) or mycophenolate mofetil (MMF), or
everolimus (CSA/EVR); sirolimus plus mycophenolate mofetil
(MMF); tacrolimus (TAC) plus sirolimus (SRL) or MMF. All
patients received 1 g methylprednisolone administered before graft
revascularization, followed by daily initial prednisone doses of 0.5
mg/kg/d (maximum of 30 mg) for 30 days. Steroid mean daily doses
and taper regimens were similar among the groups, reaching 10 mg
between 90 and 120 days. No patient underwent steroid withdrawal
during the first year. The initial drug combination was maintained
until the end of the first year after transplantation unless compli-
cated by adverse events or a lack of efficacy.Study Visits and Evaluations
Fasting TC, TG, and HDL-C, determinations used enzymatic
assays in an Hitachi 912 auto analyzer (Roche Diagnostics,
Lewes, UK). Lipid-lowering drug uses were collected pretrans-
plant as well as 30, 90, 180, 270, and 365 days
these after these. LDL-C was estimated by Friedewald’s for-
mula.12 The non-HDL-C was calculated by subtracting HDL-C
from TC.13 Biochemistry and hematology assessments were also
btained at all study visits. Creatinine clearance was calculated
sing the Cockcroft-Gault formula.14 Proteinuria was not sys-
ematically evaluated in these patients.
Definitions
Dyslipidemia was diagnosed in patients showing (1) TC  200
g/dL15; (2) LDL-C  100 mg/dL15; (3) non-HDL-C  130
g/dL15; (4) TG  150 mg/dL15; (5) HDL-C  40 mg/dL (males)
or 50 mg/dL (females)8; (6) LDL-C:HDL-L ratio  3.3 (males)
r  2.9 (females); (7) TC:HDL ratio  5.1 (males) or  4.4
females)16; (8) TG:HDL-C ratio  4.0.17 At the time of the
diagnosis of dyslipidemia, patients sequentially received dietary
and activity instructions followed by statin therapy at the discretion
of the attending physicians. New-onset diabetes after transplanta-
tion (NODAT) was defined according to the American Diabetes
Association guidelines.18
Statistical Analysis
Descriptive data and results are reported as mean values and
standard deviations for continuous variables and as frequency
distributions for categorical variables. Demographic features,
transplant outcomes, lipid profiles, and the proportions of patients
outside recommended target ranges were compared using analysis
of variance or chi-square test. Student t test was used to compare
immunosuppressive drug doses and concentrations as well as lipid
fractions and ratios. Logistic regression analysis was employed to
assess adjusted odds ratio (AOR) for the development of dyslipi-
demia at 1 year using median values of TC, TG, LDL-C, and
HDL-C as dependent variables. Covariates included recipient age,
gender, body mass index, ethnicity (black and intermediate vs
others), end-stage renal disease (diabetes vs others), time on
dialysis, donor source (living vs deceased), renal function at 30
days, NODAT, biopsy-proven acute rejection (BPAR), type of
calcineurin inhibitor (CSA vs TAC), type of adjunctive agent (SRL
or EVR vs MMF), and mean weight-normalized prednisone dose
at 30 days after transplantation. Statistical analysis was performed
using a computer statistics package (SPSS v 7.5).
RESULTS
Demographics, Immunosuppressive Regimens, and
Transplant Outcomes
Among the 474 subjects included in this analysis, patients
receiving SRL/MMF were older than those receiving CSA/
SRL or TAC/SRL (Table 1). The proportion of white
patients was lower in the CSA/SRL group. Mean time on
dialysis was longer among patients receiving TAC/MMF.
Calculated creatinine clearance at 12 months was higher in
patients receiving TAC/MMF and lower in those receiving
CSA/EVR. The incidence of first BPAR ranged from 8%
(CSA/EVR) to 34% (SRL/MMF). The incidence of NO-
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3732 SPINELLI, FELIPE, PARK ET ALDAT ranged from 6% (SRL/MMF) to 14% (TAC/SRL).
Overall more than 92% of patients were still receiving the
initial immunosuppressive regimen at 1 year. At 12 months,
CSA concentrations were significantly lower when associ-
ated with SRL or EVR compared with MMF. No differ-
ences were observed in TAC concentrations comparing
patients receiving SRL or MMF. Higher SRL concentra-
tions were observed when this drug was combined with CSA
compared with TAC or MMF. MMF doses were higher in
patients receiving CSA compared with those patients re-
ceiving SRL or TAC. Prednisone doses were lower among
patients receiving the TAC/MMF combination compared
with the other regimens.
Lipid Profiles
The concentrations of all lipid fractions increased from
pretransplant to 1 year posttransplantation (Table 2). The
time course of changes in TC and TG are shown in Fig 1.
The mean TC concentration increased 39% and the pro-
Table 1. Demographic Characteristics, Im
CSA/SRL
(n  137)
CSA/MMF
(n  58)
C
Age (y)* 36  11 39  11 3
MI (kg/m2) 23.4  4.1 23.3  3.6 24
Gender, n (%)
Male 93 (68) 33 (57)
Female 44 (32) 25 (43)
Ethnicity, n (%)*
White 44 (32) 29 (50)
Black 36 (26) 08 (14)
Mulatto 55 (40) 15 (26)
Other 02 (02) 06 (10)
Cause of ESRD, n (%)
Hypertension 28 (20) 10 (17)
Chronic glomerulonephritis 22 (16) 05 (09)
Diabetes mellitus 07 (05) 06 (10)
Other 80 (59) 37 (64)
Time on dialysis (mo)* 26.3  21.3 33.7  24.2 25
Donor source, n (%)†
Living 122 (89) 37 (64)
Deceased 15 (11) 21 (36)
Renal function
Serum creatinine (mg/dL) 1.6  0.5 1.5  0.4 2
CrCl (min/mL/1.73 m2)* 64  19 64  18 5
ODAT (%) 18 (13) 05 (09)
PAR, n (%)† 24 (17) 14 (24)
On therapy at 12 mo, n (%)† 121 (88) 52 (90)
mmunosuppression at 12 mo
CSA concentration (ng/mL) 54  42 124  66 7
TAC concentration (ng/mL) — —
SRL concentration (ng/mL) 13.3  5.4 —
EVR concentration (ng/mL) — — 7
MMF dose (mg/d) — 2.1  0.5
PRED dose (mg/d) 9.1  4.3 9.4  4.3 9
CsA, cyclosporine; SRL, sirolimus; MMF, mycophenolate mofetil; TAC, tacrol
diabetes after transplantation; BPAR, biopsy-proven acute rejection; PRED, pr
*P  .05, analysis of variance comparing all groups.
†P  .05 chi-square test among all groups.portion of patients with a TC value above 200 mg/dLncreased from 18% to 64%. Similar trends were observed
ith LDL-C and non-HDL-C fractions. In 20% of patients,
DL-C concentrations were not calculated at 12 months
ecause TG concentrations were above 400 mg/dL,12 par-
ticularly among patients receiving SRL (28%) or EVR
(38%). The mean TG concentration increased 55% and the
proportion of patients with TG above 150 mg/dL increased
from 41% to 69%. The magnitude of changes in TC and TG
at 12 months was higher among patients receiving CSA/
SRL or CSA/EVR compared with those prescribed TAC/
MMF. Mean HDL-C concentration increased 14% in males
and 22% in females resulting in a reduction (46% for males
and 52% females) in the proportion of patients with
HDL-C below recommended target at 1 year after the
transplant.
No uniform trends were observed among all calculated
lipid ratios from pretransplant to 1 year. The proportion of
patients with TC:HDL-C ratios above the recommended
target concentrations increased 95% for males and 32% for
suppression, and Transplant Outcomes
VR
7)
SRL/MMF
(n  32)
TAC/SRL
(n  86)
TAC/MMF
(n  114)
Total
(n  474)
12 44  14 36  11 42  13 39  12
4.8 24.0  4.5 23.7  3.7 24.2  3.8 23.7  4.0
7) 19 (59) 52 (60) 83 (73) 307 (65)
3) 13 (41) 34 (40) 31 (27) 167 (35)
5) 20 (63) 43 (50) 64 (56) 226 (48)
6) 01 (03) 18 (21) 12 (11) 78 (16)
3) 02 (06) 18 (21) 25 (22) 121 (26)
6) 09 (28) 07 (08) 13 (11) 49 (10)
5) 03 (09) 12 (14) 19 (17) 79 (17)
3) 06 (19) 10 (12) 15 (13) 64 (13)
2) 01 (03) 07 (08) 11 (10) 33 (07)
0) 22 (69) 57 (66) 69 (60) 298 (63)
21.7 23.5  23.6 28.2  32.6 39.4  31.0 30.4  27.1
4) 32 (100) 74 (86) 71 (62) 380 (80)
6) 0 (0) 12 (14) 43 (38) 94 (20)
1.6 1.6  0.8 1.6  0.9 1.5  1.1 1.6  0.9
20 60  20 64  17 67  19 64  19
7) 02 (06) 12 (14) 12 (10) 57 (12)
8) 11 (34) 09 (10) 13 (11) 75 (16)
8) 27 (84) 77 (89) 114 (100) 437 (92)
36 — — —
— 6.4  2.6 6.6  2.9
8.1  4.0 9.6  5.3 —
2.2 — — —
1.8  0.5 — 1.8  0.5
2.1 9.7  1.0 9.1  5.3 6.9  2.3
ESRD, end-stage renal disease; Crcl, creatinine clearance; NODAT, new-onset
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ednisofemales. Similarly, the proportion of patients with an LDL-
Table 2. Lipid Profiles Pretransplant and 12 Months Posttransplant
Lipid fraction Day CSA/SRL CSA/MMF CSA/EVR SRL/MMF TAC/SRL TAC/MMF Total
TC 0 159  40 (15) 170  47 (29) 172  49 (21) 167  43 (16) 159  41 (13) 165  42 (20) 164  43 (18)
365ab 247  58c (76)d 230  59c (65)d 278  52c (98)d 236  61c (74)d 218  65c (60)d 191  47c (36)d 228  62c (64)d
TG 0 162  116 (39) 153  82 (50) 184  155 (38) 150  167 (53) 160  117 (35) 160  97 (43) 161  110 (41)
365ab 298  203c (82)d 214  155c (60) 331  225c (80)d 256  143c (81)d 233  165c (65)d 193  142c (53) 250  181c (69)d
LDL-C 0b 85  34 (28) 94  38 (39) 98  36 (35) 90  37 (28) 79  33 (18) 90  35 (34) 88  35 (30)
365ab 136  46c (78)d 135  46c (74)d 166  39c (97)d 133  56c (70)d 118  49c (69)d 104  35c (46)d 126  47c (68)d
Missingb 39 (28) 7 (12) 18 (38) 5 (15) 9 (10) 15 (13) 93 (20)
Non-HDL-C 0b 116  40 (33) 124  45 (45) 133  46 (43) 119  42 (34) 112  41 (28) 122  41 (39) 120  42 (36)
365ab 192  56c (88) 176  55c (80) 228  53c (100) 180  61c (81) 164  60c (73) 142  44c (53) 175  59c (76)
HDL-C
Male 0 41  12 (55) 44  12 (48) 39  16 (64) 43  19 (53) 44  11 (40) 41  10 (52) 42  12 (52)
365 51  16c (24)d 50  11c (19)d 47  12 (26)d 52  10 (10)d 50  17 (32) 47  12c (40) 49  14c (28)d
Female 0a 46  16 (65) 50  11 (56) 40  10 (89) 53  19 (54) 52  15 (56) 47  12 (61) 48  14 (63)
365 65  16c (14)d 60  13c (30) 54  14c (44)d 64  18 (17) 59  16 (30) 56  11c (36) 60  15c (30)
TC:HDL-C
Male 0a 4.0  1.5 (17) 3.8  1.3 (12) 4.9  2.3 (32) 4.0  1.3 (21) 3.8  1.3 (17) 4.1  1.2 (19) 4.0  1.5 (19)
365ab 5.0  1.5c (44)d 4.3  1.1 (28) 6.4  1.9c (87)d 4.5  1.3 (47) 4.6  1.4c (26) 4.3  1.1 (22) 4.7  1.5c (37)
Female 0a 4.3  1.9 (39) 3.9  1.2 (24) 4.7  2.1 (32) 3.6  1.4 (23) 3.3  1.2 (18) 3.8  1.3 (29) 3.9  1.6 (28)
365ab 4.2  1.2 (42) 4.4  1.1 (43) 5.2  1.6 (67)d 4.3  1.9 (42) 3.9  1.2c (30) 3.4  0.8 (14) 4.1  1.3 (37)
LDL-C:HDL-C
Male 0 2.1  1.1 (10) 2.1  1.0 (6) 2.6  0.9 (23) 2.2  1.1 (10) 1.9  1.0 (10) 2.2  0.9 (14) 2.1  1.0 (12)
365ab 2.8  1.3c (27)d 2.6  08 (17) 3.6  0.9c (80)d 2.4  1.1 (20) 2.5  1.0c (16) 2.3  0.7 (8) 2.6  1.1c (21)
Female 0 2.4  1.3 (29) 2.2  1.0 (16) 2.4  0.9 (23) 2.0  1.0 (15) 1.6  0.8 (9) 2.2  1.1 (19) 2.1  1.1 (18)
365a 2.2  0.9 (21) 2.5  0.8 (24) 2.7  0.7 (29) 2.4  1.4 (25) 2.1  0.9c (16) 1.8  0.6 (4) 2.2  0.9 (18)
TG:HDL-C
0a 4.4  4.3 (36) 3.5  2.1 (31) 6.2  8.4 (45) 3.8  2.2 (47) 3.8  3.2 (27) 4.1  3.1 (38) 4.3  4.2 (36)
365ab 5.9  4.2c (44)d 4.2  3.3 (41) 7.7  6.6 (25) 5.1  3.7 (59) 5.1  5.0 (55)d 4.3  3.6 (55) 5.2  4.5c (47)
Normal lipid profile (%) 0b 25 24 21 34 42 25 28
365b 05d 11d 0d 10d 10d 20 10d
Statin use (%) 365b 40 11 32 19 40 09 27
Mean  standard deviation. In parenthesis is the proportion of patients with lipid fraction outside recommended target range [TC  200 mg/dL; TG  150 mg/dL; LDL-C  100 mg/dL; non-HDL-C  130 mg/dL;
HDL-C  40 mg/dL (male) and  50 mg/dL (female); TC/HDL-C  5.1 (male) and  4.4 (female); LDL-C/HDL-C  3.3 (male) and 2.9 (female); TG/HDL-C  4.0]. LDL-C missing values were due to high (400 mg/dL)
TG concentrations.
CSA, cyclosporine; SRL, sirolimus; MMF, mycophenolate mofetil; EVR, everolimus; SRL, sirolimus; TAC, tacrolimus; TC, total cholesterol; TG, total triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol.
aP  .05 comparing mean lipid fraction concentrations among all groups.
bP  .05 comparing proportion of patients with lipid fraction concentration outside recommended target ranges among all groups.
cP  .05 comparing pre- vs posttransplant mean lipid fraction concentrations.
dP  .05 comparing pre- vs posttransplant proportion of patients with lipid fraction concentration outside recommended target ranges.
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3734 SPINELLI, FELIPE, PARK ET ALC:HDL-C ratio above the recommended target increased
75% for males but did not change for females. For the
TG:HDL-C ratio, a 31% increase was observed at 12
months after transplantation.
Finally, the proportion of patients with normal lipid
profiles, including all lipid fractions and ratios, decreased
from 28% before transplantation to 10% at 1 year there
after. Overall, 27% of patients were prescribed a lipid-
lowering agent at 12 months, a proportion that was higher
among recipients treated with calcineurin inhibitors in
Fig 1. Box plot distribution of
time-dependent changes in to-
tal cholesterol (A) and triglycer-
ides (B) concentration accord-
ing to immunosuppressive
regimen. The boxes show the
lower, median, and upper quar-
tiles (25th, 50th, and 75th per-
centiles). Outlier (°) was defined
as a value 1.5 times lower (or
higher) than box length. Ex-
treme value (*) was defined as a
value 3 times lower (or higher)
than box length. CSA, cyclo-
sporine; SRL, sirolimus; MMF,
mycophenolate mofetil; EVR,
everolimus; SRL, sirolimus;
TAC, tacrolimus.combination with SRL or EVR. No significant differencesn overall results were observed when analyzing only those
atients who did not receive any lipid-lowering agent during
he 12-month period of observation (data not shown).
LDL-C Versus Other Lipid Fractions and Ratios
In patients with LDL-C below 100 mg/dL (31.8%), over
60% of other lipid fractions and ratios were also within
target ranges. Interestingly, among patients with LDL-C
above 100 mg/dL (68.2%), over 57% of other lipid fractions
and ratios were within target ranges (Table 3).
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LIPID PROFILE AFTER KIDNEY TRANSPLANTATION 3735Risk Factors Associated With Dyslipidemia
Using logistic regression analysis, we identified age, gender,
time on dialysis, NODAT, type of calcineurin inhibitor,
class of immunosuppressive agent, and prednisone dose to
be associated with dyslipidemia (Table 4). Risk factors
associated with higher TC concentration included age,
gender, time on dialysis, CSA use, and EVR or SRL use,
with AOR ranging from 1.6 to 3.5. Risk factors associated
with higher LDL-C excluded gender but also included
prednisone dose 30 days after transplantation (AOR of
1.6). Higher non-HDL-C concentrations were associated
with CSA use, EVR or SRL use, and development of
NODAT; the AOR ranged from 2.2 to 3.1. Finally, higher
Table 3. Proportion of Patients With Lipid Fractions or Ratios
Within Recommended Targets According to LDL-C
Concentrations 1 Year After Kidney Transplantation
Lipid fraction or
ratio (%)
LDL-C  100 mg/dL
(n  260, 68.2%)
LDL-C  100 mg/dL
(n  121, 31.8%)
Non-HDL-C  130 mg/dL 3 78
HDL-C  50 mg/dL
female
77 66
HDL-C  40 mg/dL male 79 61
Total 78 63
COL:HDL-C  4.4 female 58 93
COL:HDL-C  5.1 male 61 92
Total 60 92.6
LDL-C:HDL-C  2.9
female
74 100
LDL-C:HDL-C  3.3 male 69 99
Total 71 99.2
TG:HDL  4.0 57 67
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol.
Table 4. Risk Factors Associated With Dys
Parameters
TC  224 mg/dL L
AOR (95% CI)* P AO
Age (37 y) 2.2 (1.4–3.5) .0011 2.
BMI (23 kg/m2) 0.6847 .4080
Gender (male/female) 1.6 (1.0–2.6) .0422
Race (others/black or mulatto) 0.3080 .5789
ESRD (others/DM) 0.0292 .8644
Time on dialysis (21 mo) 1.8 (1.2–2.9) .0087 2.
Donor source (living/deceased) 0.1469 .7015
Creatinine at 30 d (1.5 mg/dL) 0.5133 .4737
ClCr at 30 d (60 min/mL/1.73m2) 0.0803 .7769
NODAT 2.0097 .1563
Acute rejection (yes/no) 0.2811 .5960
CNI (CSA/TAC) 3.5 (2.2–5.6) .001 2.
Adjunctive agent (SRL or EVR/
MMF)
2.9 (1.8–4.7) .001 2.
Prednisone dose (day 30  0.38
mg/kg)
1.2358 .2663 1.
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, hig
body mass index; ESRD, end-stage renal disease; ClCr, creatinine clearance
cyclosporine; TAC, tacrolimus; SRL, sirolimus EVR, everolimus; MMF, mycophenola
*AOR: obtained from logistic regression analysis and 95% confidence intervals.G concentrations were associated with age, development
f NODAT, and use of EVR or SRL with AOR ranging
rom 1.8 to 2.8. No risk factor was associated with lower
DL-C concentrations when the analysis was performed
ccording to gender.
DISCUSSION
Baseline demographic characteristics of our study popula-
tion showed relatively few risk factors associated with the
development of dyslipidemia after transplantation. The
population was relatively young and nonobese. It included
only a small proportion of patients with chronic kidney
disease due to diabetes (7%). Nevertheless, only 28% of
these patients showed lipid profiles within normal labora-
tory ranges before the transplant surgery, as is typically seen
among hemodialysis patients with chronic kidney disease.19
Despite differences in age, ethnicity, and dialysis time, no
significant differences were observed comparing lipid pro-
files of patients according to the immunosuppressive drug
use after transplantation.
Our study confirmed that after kidney transplantation,
there is a universal increase in all lipid fractions. At 1 year,
the proportion of patients with a normal lipid profile was
reduced to only 10%. Generally, increases in TC and TG
were observed as early as 30 days after transplant surgery,
peaking at 6 months with a trend to stabilization toward the
end of first year, regardless of the immunosuppressive
regimen (Fig 1). The overall use of statins (27%) was
low.20,21
Generally, patients receiving CSA as opposed to TAC or
SRL or EVR as opposed to MMF show worse lipid profiles
despite a higher proportion of SRL or EVR patients
prescribed statins at 1 year.22 Compared with CSA, patients
emia 1 Year After Kidney Transplantation
 121 mg/dL non-HDL-C  193 mg/dL TG  197 mg/dL
% CI) P AOR (95% CI) P AOR (95% CI) P
–3.4) .0026 2.9490 .0859 1.8 (1.2–2.8) .0071
63 .5991 0.8846 .3470 1.5378 .2150
80 .3808 0.3597 .5486 0.2842 .5940
80 .8932 0.7643 .3820 0.0417 .8382
91 .2989 0.1376 .7107 0.5595 .4544
–3.2) .0046 0.1886 .6641 0.9235 .3366
84 .9268 1.4248 .2326 1.8589 .1728
44 .8530 0.4044 .5248 0.2644 .6071
97 .8422 0.7498 .3865 1.4267 .2323
58 .2108 2.5 (1.3–4.8) .0049 2.1 (1.1–4.1) .0301
54 .4905 0.0002 .9881 0.0327 .8564
–3.8) .0004 3.1 (1.9–5.0) .001 2.2688 .1320
–3.6) .0023 2.2 (1.4–3.7) .0015 2.8 (1.8–4.4) .001
–2.6) .0497 0.0433 .8351 0.0905 .7635
sity lipoprotein cholesterol; TG, triglycerides; AOR, adjusted odds ratio; BMI,
AT, new-onset diabetes after transplantation; CNI, calcineurin inhibitor; CSA,lipid
DL-C
R (95
1 (1.3
0.27
0.76
0.01
1.07
0 (1.2
0.00
0.03
0.03
1.56
0.47
4 (1.5
2 (1.3
6 (1.0
h-den
; NODte mofetil; DM, diabetes mellitus.
f
c
T
a
i
d
3736 SPINELLI, FELIPE, PARK ET ALreceiving TAC showed less increase in TC but similar
increases in TG concentrations. Conversion from CsA to
TAC can result in a decrease of LDL-C and TG levels but
no change in HDL-C levels.23 Finally, chronic corticoste-
roid use is associated with increases in TC, TG, and
HDL-C.24
Current guidelines suggest that treatment of dyslipide-
mia should aim at LDL-C concentrations below 100
mg/dL among the general population. It is also recom-
mended that kidney transplant recipients be considered
in the highest-risk category, equivalent to that of patients
with known coronary heart disease. Nevertheless, only
one robust prospective clinical trial in a low-risk kidney
transplant population showed that treatment of dyslipi-
demia achieving a 32% reduction in LDL-C concentra-
tions was associated with fewer cardiac deaths or nonfa-
tal myocardial infarctions.25 On the other hand, all lipid
ractions and ratios have been shown to be predictors of
oronary heart disease in the general population.26 High
G concentrations are also an independent risk factor
ssociated with coronary heart disease.27 In epidemiolog-
cal studies, non-HDL-C concentration was superior pre-
ictor of cardiovascular risk compared with LDL-C.28
Among our cohort of patients, a high proportion of
patients with LDL-C below 100 mg/dL also showed other
lipid fractions and ratios within target ranges. More
importantly, 57% to 79% of patients with LDL-C above
100 mg/dL also showed other lipid fractions and ratios
within target ranges. Based on the recognized predictive
value of all these lipid fractions and ratios for cardiovas-
cular events, it is difficult to evaluate risk based on the
changes observed among this patient cohort. This pattern
of lipid changes and the direct or indirect effects of
SRL/EVR and other immunosuppressive agents, includ-
ing antiproliferative effects, may influence the develop-
ment and progression of atherosclerotic cardiovascular
disease in kidney transplant patients.24
The limitations of our study include its retrospective
nature and the lack of information on proteinuria and on
smoking. It was not our intention to associate lipid profiles
with cardiovascular outcomes. This would require longer
follow-up, taking into account the sample size of this
population and the relatively low rate of cardiovascular
events.
In summary, lipid profiles change significantly early and
almost universally at 1 year after kidney transplantation,
with significant influences of demographic characteristics,
clinical events, and the type of immunosuppressive drug.
Inconsistent changes in lipid fractions and ratios, comor-
bidities, deterioration of allograft function, the differential
effects of immunosuppressive drugs on the development of
atherosclerosis, and drug-drug interactions all affect these
moieties, possibly reducing the predictive value of LDL-C
to predict cardiovascular events among the kidney trans-
plant population.REFERENCES
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